Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Table 5 Maximum reduction in the sum of lesions and a single lesion after samalizumab dosing

Samalizumab Treatment Group	Patient ID	Single Lesion^b		Sum of Lesions^b
Samalizumab Treatment Group	Patient ID	% Change	Cycle Day	% Change	Cycle Day
50 mg/m² (N = 4)	101–103	−3.45	C1 D28	2.77	C1 D28
	101–104	−45.29	C1 D77	−9.8	C1 D35
	102–101	−19.75	C4 D16	4.32	C4 D16
	102–102	−9.77	C1 D35	−9.46	C1 D35
100 mg/m² (N = 4)^a	101–202	−37.78	C4 D0	−6.83	C4 D0
	101–203	−11.54	C4 D0	7.0	C1 D28
	102–201	−95.31	C4 D0	−20.7	C4 D0
	102–205	−41.36	C3 D26	−18.7	C3 D26
200 mg/m² (N = 2)^a	101–301	− 48.67	C1 D28	−28.7	C1 D28
200 mg/m² (N = 2)^a	102–303	−42.05	C3 D21	−4.75	C3 D21
300 mg/m² (N = 3)	101–402	−14.29	C4 D43	8.3	C4 D43
	101–403	−23.81	C1 D29	−12.5	C1 D29
	102–401	−58.73	C1 D35	−16.1	C16 D1
400 mg/m² (N = 3)	102–502	−87.02	C13 D35	−63.4	C13 D35
	107–503	−54.55	C4 D27	−3.34	C1 D42
	107–504	−29.34	C1 D29	9.52	C1 D29
500 mg/m² (N = 4)^a	101–606	−48.15	C6 D0	−6.91	C6 D0
	102–601	−86.36	C2 D28	−73.7	C2 D28
	102–603	−5.13	C1 D25	1.84	C1 D25
	102–607	−37.36	C1 D28	−19.4	C1 D28

^aPatient 107–602 (500 mg/m² cohort) did not have a post-dose CT scan and was not evaluable; Patients 104–204 (100 mg/m² cohort) and 104–302 (200 mg/m² cohort) had no reduction in any of their target lesions and are not included
^bMaximum reduction for a single lesion (product of bi-dimensional tumor measurement) and maximum reduction for sum of lesions (sum of the products of bi-dimensional tumor measurements) are presented as a % Change from baseline on the indicated Cycle and Day